|Bid||22.58 x 1000|
|Ask||22.63 x 1100|
|Day's Range||22.52 - 22.90|
|52 Week Range||5.44 - 26.40|
|Beta (5Y Monthly)||0.64|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 11, 2020 - Mar 15, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||28.00|
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Jan. 14.) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ...
The Offer is made upon the terms and subject to the conditions described in the offer to purchase and in the related letter of transmittal. The closing price of XBiotech’s common shares on the NASDAQ Global Select Market on January 13, 2020, the last full trading day before the commencement of the Offer, was $18.62 per share.
XBiotech Inc. (XBIT) announced today closing of the sale of the Company’s True Human antibody Bermekimab to Janssen Biotech, Inc. (Janssen), a Janssen Pharmaceutical Company of Johnson & Johnson. Upon closing, Janssen paid XBiotech $750 million, with $75 million held in escrow for 18 months. Should Janssen pursue bermekimab indications outside of dermatology, XBiotech could also receive up to $600 million in additional payments upon completion of certain commercialization authorizations.
"The global economic environment is very favorable for investors. Economies are generally strong, but not too strong. Employment levels are among the strongest for many decades. Interest rates are paused at very low levels, and the risk of significant increases in the medium term seems low. Financing for transactions is freely available to good borrowers, […]
XBiotech Inc. (XBIT) announced today that the company was selected for addition to the NASDAQ Biotechnology Index (NASDAQ:NBI). The biotechnology index is classified according to the Industry Classification Benchmark (ICB). Companies in the biotechnology index must meet eligibility requirements, including minimum market capitalization, average daily trading volume, seasoning as a public company, and other criteria.
A string of multibillion-dollar pharmaceutical deals announced over the last week call attention to a record-setting year in which drugmakers and biotechs have spent $342 billion snapping up smaller companies to bolster their pipelines.
XBiotech Inc. (XBIT) announced today that it has entered into a definitive agreement with Janssen Biotech, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson, to sell XBiotech’s novel antibody (bermekimab) that neutralizes interleukin-1 alpha (IL-1⍺). Janssen will acquire all rights to bermekimab under the terms of the agreement, and XBiotech will be free to use its True Human Antibody discovery program to develop new antibody therapeutics that target IL-1⍺ to treat non-dermatological diseases.
AUSTIN, Texas, Nov. 19, 2019 -- XBiotech Inc. (NASDAQ: XBIT) today announces rapid enrollment in its randomized, double-blind, placebo-controlled Phase 2 clinical study.
XBiotech Inc. (XBIT) has enrolled the first patient in a randomized, double-blind, placebo-controlled Phase 2 clinical study to evaluate its IL-1a blocking antibody therapy in patients with moderate to severe Atopic Dermatitis (AD) (also known as Eczema). Chaired by award-winning dermatologist Seth B. Forman, MD, of ForCare Medical Group in Tampa, FL, the study will assess weekly bermekimab therapy to reduce inflammatory skin lesions, itch, and pain in patients suffering from eczema. The study will compare three groups of patients over 16 weeks of treatment: a weekly dosing group, a biweekly dosing group, and a placebo group.
XBiotech Inc. (XBIT) announced today that the first patient was enrolled in its randomized, double-blind, placebo-controlled Phase 2 clinical study evaluating bermekimab in patients with moderate to severe Hidradenitis Suppurativa (HS). The study is chaired by renowned investigative dermatologist Alice Gottlieb, MD, PhD, Medical Director of dermatology at the Mount Sinai Beth Israel Campus and Clinical Professor at the Icahn School of Medicine at Mount Sinai. The study’s primary endpoint is the percentage of subjects achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at week 12.
AUSTIN, Texas, Oct. 02, 2019 -- XBiotech (NASDAQ: XBIT) announced the first patient was enrolled in a clinical study evaluating bermekimab therapy in adults with systemic.
XBiotech (XBIT) announced today that Dr. Alice Gottlieb will be presenting clinical findings for bermekimab in the treatment of atopic dermatitis (AD) at the European Academy of Dermatology and Venereology (EADV) Congress being held in Madrid Spain October 9-13th. Dr. Gottlieb will present data from a multicenter, phase 2 study in which bermekimab monotherapy showed rapid and dose dependent improvement in AD. The presentation will be given during the October 12th morning session for late breaking clinical data, Chaired by Professor Brigitte Dreno.
XBiotech Inc. (XBIT) announced today that the Canadian Patent Office has granted XBiotech a patent (Patent Number 56003542-6CA) covering the use of bermekimab in the treatment of inflammatory skin diseases. The patent describes studies showing that antibodies which specifically neutralize the activity of interleukin-1alpha (IL-1α), such as bermekimab, reduce skin inflammation and treat inflammatory skin diseases. XBiotech has conducted a number of clinical trials in dermatology using bermekimab, including studies in hidradenitis suppurativa, atopic dermatitis, and psoriasis vulgaris (plaque psoriasis).
XBiotech (XBIT) announces that Seth Forman, M.D., will Chair the Company’s upcoming randomized, double-blind, placebo controlled Phase 2 study in Atopic Dermatitis (AD). This second Phase 2 study of bermekimab to treat moderate to severe AD in adults will build on results of a recently completed randomized study that showed rapid improvement in inflammatory lesions and pruritus.
XBiotech Inc. (XBIT) announced today that Peter Libby, M.D., has been appointed to the Company’s Corporate Board of Directors. Dr. Libby has played a pioneering role in discovering how inflammation leads to cardiovascular disease. Dr. Libby is a practicing cardiovascular specialist at Brigham and Women’s Hospital in Massachusetts and he is Mallinckrodt Professor of Medicine at Harvard Medical School.
XBiotech (XBIT) announced today that the Medical Research Council (MRC), part of UK Research and Innovation, has awarded funding to study bermekimab therapy in a Phase 2 multi-center study in advanced cancers.
XBiotech Inc. (XBIT) announced today that it is the recipient of the first place 2019 Commercial Real Estate Award for Industrial Development, chosen by the Austin Business Journal. XBiotech USA Inc. received the award for its integrated R&D, administrative, and manufacturing facility located just 15 minutes from downtown Austin. XBiotech began construction of its state-of-the-art facility in 2015 as part of a master plan to build its worldwide operations headquarters.
XBiotech (XBIT) announces that Alice Gottlieb M.D., Ph.D., will Chair the Company’s upcoming Phase II study in Hidradenitis Suppurativa (HS). Dr. Gottlieb is Medical Director of dermatology at the Mount Sinai Beth Israel Campus, and Clinical Professor at the Icahn School of Medicine at Mount Sinai.
XBiotech Inc. (XBIT) announced today that the Company has been added to the preliminary list of the broad market Russell 3000® Index, which will take effect after US market close on June 28, as part of the 2019 Russell indexes reconstitution. Membership in the Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index as well as the appropriate growth and value style indexes. Annual reconstitution of the Russell indexes captures the 4,000 largest US stocks as of May 10th, ranking them by total market capitalization.
XBiotech Inc. (XBIT) today announced the closing of its previously announced underwritten public offering of 4,848,485 of its common shares at a public offering price of $8.25 per share. In addition, XBiotech has granted the underwriter a 30-day option to purchase up to an additional 351,515 common shares at the public offering price, less underwriting discounts and commissions. Piper Jaffray acted as the sole underwriter in the offering.
XBiotech Inc. (XBIT) today announced the pricing of an underwritten public offering of 4,848,485 of its common shares at a public offering price of $8.25 per share. The offering is expected to close on or about June 4, 2019, subject to the satisfaction of customary closing conditions. In addition, XBiotech has granted the underwriter a 30-day option to purchase up to an additional 351,515 common shares at the public offering price, less underwriting discounts and commissions. Piper Jaffray is acting as the sole underwriter in the offering.
XBiotech Inc. (XBIT) today announced that it has commenced an underwritten public offering of common shares, subject to market and other conditions. XBiotech intends to grant the underwriter in the offering a 30-day option to purchase additional common shares. Piper Jaffray is acting as the sole underwriter in the offering. The common shares are being offered pursuant to an effective shelf registration statement on Form S-3 previously filed with and declared effective by the Securities and Exchange Commission. The prospectus supplement and accompanying prospectus relating to the offering contain important information relating to the XBiotech common shares.
XBiotech (XBIT) announced plans to advance its dermatology program for its true human antibody bermekimab with the launch of a randomized, double-blind, placebo controlled, Phase 2b clinical study in patients with moderate to severe Hidradenitis Suppurativa (HS). This Phase 2b study will evaluate safety and efficacy of bermekimab at different subcutaneous doses compared with placebo. The Company expects the first patient to be enrolled during the third quarter of 2019.